← All trials
NCT05848713
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2023
- Primary completion
- Mar 31, 2028
- Completion date
- Mar 31, 2029
- First posted
- May 8, 2023
- Last posted
- Nov 8, 2023
- Enrollment
- 4000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ManitobaLead sponsor
- Canadian Critical Care Trials GroupCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) NetworkCollaborator
- Ozmosis Research Inc.Collaborator
- Research ManitobaCollaborator
- University of ManitobaOverall official - principal investigator
- University of ManitobaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.